FUROSCIX Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Furoscix, and when can generic versions of Furoscix launch?

Furoscix is a drug marketed by Scpharmaceuticals and is included in one NDA. There are three patents protecting this drug.

This drug has twenty-four patent family members in fifteen countries.

The generic ingredient in FUROSCIX is furosemide. There are twenty-two drug master file entries for this compound. Fifty-seven suppliers are listed for this compound. Additional details are available on the furosemide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Furoscix

A generic version of FUROSCIX was approved as furosemide by HIKMA on November 10^th, 1983.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for FUROSCIX?
What are the global sales for FUROSCIX?
What is Average Wholesale Price for FUROSCIX?

Summary for FUROSCIX

International Patents:	24
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	137
Clinical Trials:	2
Patent Applications:	3,302
Drug Prices:	Drug price information for FUROSCIX
What excipients (inactive ingredients) are in FUROSCIX?	FUROSCIX excipients list
DailyMed Link:	FUROSCIX at DailyMed

Drug patent expirations by year for FUROSCIX

Recent Clinical Trials for FUROSCIX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Texas Southwestern Medical Center	Phase 2
scPharmaceuticals, Inc.	Phase 2
scPharmaceuticals, Inc.	Phase 1

See all FUROSCIX clinical trials

Pharmacology for FUROSCIX

Drug Class	Loop Diuretic
Physiological Effect	Increased Diuresis at Loop of Henle

US Patents and Regulatory Information for FUROSCIX

FUROSCIX is protected by three US patents and one FDA Regulatory Exclusivity.

Patents protecting FUROSCIX

Pharmaceutical formulations for subcutaneous administration of furosemide
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Pharmaceutical formulations for subcutaneous administration of furosemide
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF A LIQUID FORMULATION COMPRISING FUROSEMIDE TO TREAT CONGESTION DUE TO FLUID OVERLOAD (EDEMA) IN ADULTS WITH NYHA CLASS II/III CHRONIC HEART FAILURE

FDA Regulatory Exclusivity protecting FUROSCIX

NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Scpharmaceuticals	FUROSCIX	furosemide	SOLUTION;SUBCUTANEOUS	209988-001	Oct 7, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Scpharmaceuticals	FUROSCIX	furosemide	SOLUTION;SUBCUTANEOUS	209988-001	Oct 7, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Scpharmaceuticals	FUROSCIX	furosemide	SOLUTION;SUBCUTANEOUS	209988-001	Oct 7, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for FUROSCIX

See the table below for patents covering FUROSCIX around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Singapore	11201508251R	PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDE	⤷ Sign Up
Singapore	10201709388Q	PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDE	⤷ Sign Up
Portugal	2981258		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration